Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer-Reference-Cited by-同舟云学术

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer

Published:2019-01-31 Issue:3 Volume:8 Page:1258-1268
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Watanabe Satomi¹,Yonesaka Kimio¹^ORCID,Tanizaki Junko¹,Nonagase Yoshikane¹,Takegawa Naoki¹,Haratani Koji¹,Kawakami Hisato¹,Hayashi Hidetoshi¹^ORCID,Takeda Masayuki¹,Tsurutani Junji¹²,Nakagawa Kazuhiko¹

Affiliation:

1. Department of Medical Oncology Kindai University Faculty of Medicine Osaka‐Sayama, Osaka Japan

2. Advanced Cancer Translational Research Institute, Showa University Tokyo Japan

Funder

Daiichi-Sankyo

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.1995

Reference29 articles.

1. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy

2. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

3. Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review

4. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

5. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance;Cancer Letters;2024-09

2. HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review;Medicine;2024-06-14

3. L’immunocytokine FAP-IL2v: Un co-traitement efficace pour pallier la résistance au trastuzumab du cancer du sein HER2⁺;médecine/sciences;2024-06

4. Disrupting EGFR–HER2 Transactivation by Pertuzumab in HER2-Positive Cancer: Quantitative Analysis Reveals EGFR Signal Input as Potential Predictor of Therapeutic Outcome;International Journal of Molecular Sciences;2024-05-29

5. Plant-Derived Anti-Human Epidermal Growth Factor Receptor 2 Antibody Suppresses Trastuzumab-Resistant Breast Cancer with Enhanced Nanoscale Binding;ACS Nano;2024-05-20